Summit Therapeutics
SMMT • NASDAQ
Summit Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Robert W. Duggan, with a market cap of $12.9B.
CEORobert W. Duggan
Next Earnings
Upcoming earnings announcement for Summit Therapeutics
Date
Thursday, April 30, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.25
Revenue Estimate
$48.3K
Earnings History
Past 12 earnings reports for Summit Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 23, 2026 | Q4 2025 | -$0.14Est: -$0.10 | -40.0% | -Est: $56.8M | -100.0% |  10-K |
| Oct 20, 2025 | Q3 2025 | -$0.13Est: -$0.08 | -62.5% | -Est: $56.9M | -100.0% | 10-Q |
| Aug 11, 2025 | Q2 2025 | -$0.12Est: -$0.08 | -50.0% | - | — | 10-Q |
| May 1, 2025 | Q1 2025 | -$0.07Est: -$0.09 | +22.2% | - | — | 10-Q |
| Feb 24, 2025 | Q4 2024 | -$0.07Est: -$0.08 | +12.5% | - | — | 10-K |
| Oct 30, 2024 | Q3 2024 | -$0.05Est: -$0.07 | +28.6% | - | — | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$0.05Est: -$0.06 | +16.7% | - | — | 10-Q |
| May 1, 2024 | Q1 2024 | -$0.06 | — | - | — | 10-Q |
| Feb 20, 2024 | Q4 2023 | -$0.05 | — | - | — | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.03 | — | - | — | — |
| Aug 9, 2023 | Q2 2023 | -$0.02 | — | - | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$1.43 | — | - | — | — |